CN108619490A - 一种长效化突变的人源成纤维生长因子的新用途 - Google Patents
一种长效化突变的人源成纤维生长因子的新用途 Download PDFInfo
- Publication number
- CN108619490A CN108619490A CN201710172824.0A CN201710172824A CN108619490A CN 108619490 A CN108619490 A CN 108619490A CN 201710172824 A CN201710172824 A CN 201710172824A CN 108619490 A CN108619490 A CN 108619490A
- Authority
- CN
- China
- Prior art keywords
- nonalcoholic steatohepatitis
- caused
- lipolysaccharide
- application according
- actingization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000018233 Fibroblast Growth Factor Human genes 0.000 title claims abstract description 9
- 108050007372 Fibroblast Growth Factor Proteins 0.000 title claims abstract description 9
- 230000035772 mutation Effects 0.000 title claims abstract description 9
- 229940126864 fibroblast growth factor Drugs 0.000 title claims abstract description 8
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims abstract description 62
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 210000002966 serum Anatomy 0.000 claims description 17
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 12
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 230000007863 steatosis Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000006454 hepatitis Diseases 0.000 claims description 7
- 231100000283 hepatitis Toxicity 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 6
- 108010082126 Alanine transaminase Proteins 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 210000005229 liver cell Anatomy 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- -1 sublimed preparation Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000004925 denaturation Methods 0.000 claims description 3
- 230000036425 denaturation Effects 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000006196 drop Substances 0.000 claims description 2
- 208000007345 glycogen storage disease Diseases 0.000 claims description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 206010048215 Xanthomatosis Diseases 0.000 claims 1
- 239000011805 ball Substances 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 description 22
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 description 22
- 239000002904 solvent Substances 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 210000004185 liver Anatomy 0.000 description 12
- 101710105284 Sialin Proteins 0.000 description 6
- 230000000857 drug effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 208000010706 fatty liver disease Diseases 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 235000002639 sodium chloride Nutrition 0.000 description 4
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010022355 Fibroins Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 101000685693 Mus musculus Sialin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000013231 NASH rodent model Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 208000004622 abetalipoproteinemia Diseases 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- VHGDODPKQBTSJN-UHFFFAOYSA-H gold(3+);tricarbonate Chemical compound [Au+3].[Au+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O VHGDODPKQBTSJN-UHFFFAOYSA-H 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- KOUKXHPPRFNWPP-UHFFFAOYSA-N pyrazine-2,5-dicarboxylic acid;hydrate Chemical compound O.OC(=O)C1=CN=C(C(O)=O)C=N1 KOUKXHPPRFNWPP-UHFFFAOYSA-N 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及一种长效化突变的人源成纤维生长因子的新用途，其中所述长效化突变的人源成纤维生长因子为脂糖素，其中所述新用途是在制备治疗非酒精性脂肪肝炎的药物中的应用。
Description
技术领域
本发明属于生物医药领域，具体涉及一种长效化的突变的人源成纤维细胞生长因子-21在治疗非酒精性脂肪肝炎药物中的应用。
背景技术
非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD),又称非酒精性脂肪肝(non-alcoholic fatty liver),是由多种原因引起,病变主体在肝小叶,以肝实质细胞脂肪变性和甘油三醋(triglyceride,TG)蓄积(肝组织脂含量超过肝湿量的5％以上,或在组织学上有1/3以上肝细胞脂肪化)为特征,病理学改变与酒精性肝病(alcoholicliver disease,ALD)相似,但无过量饮酒史(折合乙醇量男性〈140g/周、女性〈70g/周)和其他明确的损肝因素的临床病理综合征。
非酒精性脂肪性肝病的疾病谱包括非酒精性单纯性脂肪肝(non-alcoholicfatty liver,NAFL)、非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)及非酒精性脂肪性肝硬化(non-alcoholic cirrhosis,NAC)和肝细胞癌。
近20年来非酒精性脂肪肝病(NAFLD)以及非酒精性脂肪肝炎(NASH)已成为西方国家肝病的首要病因。非酒精性脂肪肝病如此时未能得以及时控制，脂肪继续过度累积变性易进展为非酒精性脂肪肝炎。非酒精性脂肪肝炎与非酒精性脂肪肝病的区别在于除脂肪的过度积累以外，肝部出现炎症细胞浸润、不同程度的纤维化以及肝细胞的损害。另外，如果非酒精性脂肪肝炎未得到有效控制而继续进展，则极易导致肝纤维化、肝硬化甚至肝癌的发生。
目前对于NASH疾病临床尚无可长期应用,安全有效的药物。
成纤维细胞生长因子-21(fibrobla st growth factor21，FGF-21)是近期发现的体内又一个代谢调节因子，属于成纤维细胞生长因子家族，其特异性作用于肝脏、脂肪、胰岛细胞且不依赖于胰岛素有效安全地调节血糖血脂的能力深得研究人员青睐，也有报道成纤维细胞生长因子-21(FGF21)可以有效的防治体外诱导的NAFLD(刘敏等，成纤维细胞生长因子-21对体外诱导的非酒精性脂肪肝细胞模型脂代谢的影响，吉林大学学报，2012年5月，第38卷第3期，477-481)
CN2013101152100(公开号为CN103193878A)隶属于哈尔滨博翱生物医药技术开发有限公司，公开了一种新的长效化突变的人源成纤维生长因子及聚乙二醇的交联物，聚乙二醇交联物的蛋白质结构为序列4，其制备方法见该文献中的实施例4，后来本发明的发明人将其命名为脂糖素。
脂糖素有调节血糖，降低血液中甘油三酯和调节总体胆固醇等功效，但是目前没有使用脂糖素治疗非酒精性脂肪肝炎方面的报道。
发明内容
本发明提供了长效化突变的人源成纤维生长因子在治疗非酒精性脂肪肝炎的药物中的应用。
所述长效化突变的人源成纤维生长因子为脂糖素或其盐，其序列见CN2013101152100(公开号为CN103193878A)的序列4：
本发明所述应用，包括：脂糖素或其盐可以降低血清中血清中谷丙转氨酶(ALT)及谷草转氨酶(AST)水平、改善脂肪变性程度、改善肝小叶炎症程度、降低肝细胞气球样变性程度和改善肝脏损伤程度。
本发明所述的非酒精性脂肪肝炎，其包括但不限于肝炎引起的非酒精性脂肪肝炎、肥胖症引起的非酒精性脂肪肝炎、糖尿病引起的非酒精性脂肪肝炎、胰岛素抵抗引起非酒精性脂肪肝炎、高甘油三酯血症引起的非酒精性脂肪肝炎、无β脂蛋白血症引起的非酒精性脂肪肝炎、糖原贮积病引起的非酒精性脂肪肝炎、韦克病引起的非酒精性脂肪肝炎、沃尔曼病引起的非酒精性脂肪肝炎和脂肪营养不良所引起的非酒精性脂肪肝炎等。
其中所述药物是含有本发明脂糖素或其药用盐作为药物活性成分的的药物组合物，所述药物组合物可以被制备成任何一种可药用的剂型，这些剂型包括：片剂、胶囊剂、颗粒剂、丸剂、散剂、膏剂、丹剂、粉剂、溶液剂、注射剂、栓剂、喷雾剂、滴剂、贴剂，本发明的药物优选注射用药物，如制备成粉针或液体针，所述液体针如水针，有机溶剂针，混悬液针等。
本发明的药物组合物，其口服给药的制剂可含有常用的赋形剂，诸如粘合剂、填充剂、稀释剂、压片剂、润滑剂、崩解剂、着色剂、调味剂和湿润剂。适用的填充剂包括淀粉、蔗糖、纤维素、甘露糖醇、乳糖和其它类似的填充剂。适宜的崩解剂包括淀粉、聚乙烯吡咯烷酮和淀粉衍生物，例如羟基乙酸淀粉钠。适宜的润滑剂包括，例如硬脂酸镁。可通过混合，填充，压片等常用的方法制备固体口服组合物。进行反复混合可使活性物质分布在整个使用大量填充剂的那些组合物中；常用的辅料成分包括：甘露醇、山梨醇、焦亚硫酸钠、亚硫酸氢钠、硫代硫酸钠、盐酸半胱氨酸、巯基乙酸、蛋氨酸、维生素C、EDTA二钠、EDTA钙钠，一价碱金属的碳酸盐、醋酸盐、磷酸盐或其水溶液、盐酸、醋酸、硫酸、磷酸、氨基酸、氯化钠、氯化钾、乳酸钠、木糖醇、麦芽糖、葡萄糖、果糖、右旋糖苷、甘氨酸、淀粉、蔗糖、乳糖、甘露糖醇、硅衍生物、纤维素及其衍生物、藻酸盐、明胶、聚乙烯吡咯烷酮、甘油、吐温80、琼脂、碳酸钙、碳酸氢钙、表面活性剂、聚乙二醇、环糊精、β-环糊精、磷脂类材料、高岭土、滑石粉、硬脂酸钙、硬脂酸镁等。
本发明的药物组合物在使用时根据疾病的状况确定用法用量，可以每日服1-6次，每次1-10个剂量单位，每个剂量单位可以是0.1mg-1000mg。
本发明提供的脂糖素的新用途具有以下优点：
脂糖素可以显著降低血清中谷丙转氨酶(ALT)及谷草转氨酶(AST)水平)改善脂肪变性程度、改善肝小叶炎症程度、降低肝细胞气球样变性程度、改善肝脏损伤程度的病理评分。最终结果证明本发明可以用于治疗非酒精性脂肪肝炎，且效果优于现有技术。
具体实施方式
以下通过实施例进一步说明本发明。
本发明使用的脂糖素，其制备方法可以参见CN2013101152100(公开号为CN103193878A)的实施例4。
实施例1：水针的制备
1、组成：脂糖素蛋白(浓度为10mg/mL)、组氨酸(药用级，浓度为10mg/mL)、柠檬酸-柠檬酸钠缓冲液(20mM柠檬酸钠-柠檬酸，100mMNaCl，pH5.5±0.1)。
2、制备方法：
1)浓度为12.5mg/mL脂糖素蛋白原液，缓冲体系为柠檬酸-柠檬酸钠，调节pH为5.5±0.1，备用；
2)浓度为50mg/mL组氨酸母液，缓冲体系为柠檬酸-柠檬酸钠缓冲液，调节pH为pH5.5±0.1，备用；
3)将步骤1)的脂糖素蛋白原液与步骤2)的组氨酸母液按照体积比为4：1配比，以500μL/支的规格灌装至2mL西林瓶。
实验例1：脂糖素在有效剂量范围内对蛋氨酸及胆碱缺乏饮食(MCD diet)诱导的非酒精性脂肪性肝炎(non-alcoholic steatohepatitis，NASH)小鼠模型的治疗作用。
本实验选用蛋氨酸胆碱缺乏饲料(MCD)诱导小鼠NASH模型，主要是由于该种饲料的应用已经有超过四十年的历史，其生产工艺越发成熟且引发表征也已经得到了多方验证，因其快速性(约4周即可引发NASH相关症状)和有效性(诱发症状与人类NASH有很大相似性)。
1、实验方法：
将八周龄C57BL雄性小鼠适应性饲养两周后开始蛋氨酸及胆碱缺乏(MCD)饲料饲喂，MCD饲料饲喂两周后根据动物体重随机分为四组，为溶剂组，FGF21组，脂糖素低剂量组，脂糖素高剂量组，每组动物10只，给药方式为皮下注射每日1次,给药,给药周期为2周。
动物分组及给药情况具体情况见表1所示：
表1：动物分组及给药情况
| 组别 | 动物数目(只) | 剂量 | 给药周期(天) |
| 溶剂组 | 10 | 同体积溶剂 | 14天 |
| FGF21组 | 10 | 0.4mg/kg/d | 14天 |
| 脂糖素低剂量组 | 10 | 0.125mg/kg/d | 14天 |
| 脂糖素高剂量组 | 10 | 2mg/kg/d | 14天 |
给药结束后处死小鼠并摘取相关组织进行后续分析。
2、检测指标
2.1分离血清，检测血清中各种生化指标：血清谷丙转氨酶(ALT)，谷草转氨酶(AST)含量使用临床通用测定试剂盒测定(申索佑福)；
2.2小鼠肝脏组织形态学检测。通过H&E染色方法观察小鼠肝脏形态变化，其具体步骤为：将新鲜取下的小块肝脏固定在福尔马林溶液中过夜，经过梯度脱水后再浸蜡，包埋切片至5um，采用苏木素-伊红染液将肝脏切片进行染色，最后在显微镜下观察各个小鼠肝脏组织的形态。
2.3小鼠肝脏组织胶原纤维检测。通过天狼星红(Sirius Red，SR)染色方法观察小鼠肝脏的胶原沉积，其具体步骤为：将石蜡块切出的小鼠肝脏切片采用Sirius Red染色试剂盒进行染色，最后在显微镜下观察各个小鼠肝脏组织的纤维化情况。
临床上设定了对非酒精性脂肪性肝炎的严重程度的评分标准(NASH ClinicalResearch Network scores)，主要包括三方面：脂肪变性(steatosis)，肝小叶炎症(lobular inflammation)和肝细胞气球样变性(ballooning)。本试验将从每组随机选五只小鼠，在对应小鼠的肝组织H&E染色切片上随机选五个视野从上述三方面进行评分，客观评价各组小鼠的肝炎病变程度。
3、数据统计和分析应用SPSS16.0统计学软件分析，两组数据之间采用t检验、多组数据之间采用One-way ANOVA检验、多元线性回归分析，以P<0.05为差异有统计学意义。
4、实验结果：
4.1脂糖素对血清中谷丙转氨酶(ALT)水平的影响：见表2
表2脂糖素对血清中谷丙转氨酶(ALT)水平的影响
| 溶剂组 | FGF21组 | 脂糖素低剂量组 | 脂糖素高剂量组 | |
| 血清ALT(U/L) | 199.8±30.8 | 100.2±20.6* | 51.1±7.7***Δ | 39.9±4.1***Δ |
注：(1)表中所示数据均为均值±标准误；(2)*,与溶剂组相比P<0.05,***,与溶剂组相比P<0.001,Δ,与FGF21组相比P<0.05。
表2结果显示：经2周治疗后发现，FGF-21组非酒精性脂肪性肝炎小鼠ALT水平降低至100.2±20.6U/L，且与溶剂组199.8±30.8U/L相比有显著性差异(P<0.05)，脂糖素低剂量组及高剂量组ALT水平分别降低至51.1±7.7U/L及39.9±4.1U/L，且与溶剂组有极显著差异(P<0.001)，与FGF21组相比也有显著差异(P<0.05)均说明脂糖素不但具有降低ALT水平的药效而且其药效优于FGF21组。
4.2脂糖素对血清中血清中谷草转氨酶(AST)水平的影响：见表3
表3脂糖素对血清中血清中谷草转氨酶(AST)水平的影响
注：(1)表中所示数据均为均值±标准误；(2)*,与溶剂组相比P<0.05,**,与溶剂组相比P<0.01,Δ,与FGF21组相比P<0.05。
表3结果显示：经2周治疗后发现，FGF21组非酒精性脂肪性肝炎小鼠AST水平降低至115.7±15.9U/L，且与溶剂组196.9±29.3U/L相比有显著性差异(P<0.05)，脂糖素低剂量组及高剂量组ALT水平分别降低至74.4±7.9U/L及73.7±7.8U/L，且与溶剂组有极显著差异(P<0.01)，与FGF21组相比也有显著差异(P<0.05)说明脂糖素不但具有降低ALT水平的药效而且其药效优于FGF21组。
4.3对NASH临床相关评分的改善作用：见表4
表4对NASH临床相关评分的改善作用
注：(1)表中所示数据均为均值±标准误；(2)*，与溶剂组相比P<0.05，**，与溶剂组相比P<0.01，***，与溶剂组相比P<0.001，Δ，与FGF21组相比P<0.05，ΔΔ，与FGF21组相比P<0.01，ΔΔΔ，与FGF21组相比P<0.001。
表4结果显示：经2周治疗后，FGF21处理组与溶剂组相比，尽管肝细胞气球样变性以及NASH总评分均有显著改善(P<0.05)，但对肝细胞炎症无显著改善(P>0.05)。脂糖素低剂量组及高剂量组与溶剂组相比在肝小叶炎症、肝细胞气球样变性以及NASH总评分上均有极显著改善。另外，脂糖素高剂量组在脂肪变性水平上也显著优于溶剂组。另外，脂糖素处理组在脂肪变性、肝小叶炎症、肝细胞气球样变性以及NASH总评分上均显著优于FGF-21处理组。以上结果说明脂糖素不但具有改善肝小叶炎症、肝细胞气球样变性以及NASH总评分的药效而且其药效显著优于FGF21处理组。
5、实验结果：
通过在注射脂糖素检测发现，脂糖素与溶剂组及FGF21组相比可以显著降低血清中血清中谷丙转氨酶(ALT)及谷草转氨酶(AST)水平，改善脂肪变性程度，肝小叶炎症程度，降低肝细胞气球样变性程度，改善肝脏损伤程度的病理评分。以上结果说明脂糖素具有治疗非酒精性脂肪肝炎的作用。
6、结论：脂糖素具有治疗非酒精性脂肪肝炎的临床应用价值，且优于现有技术。
Claims (9)
1.一种长效化突变的人源成纤维生长因子在制备治疗非酒精性脂肪肝炎的药物中的应用。
2.根据权利要求1所述的应用，其特征在于，所述长效化突变的人源成纤维生长因子为脂糖素或其药用盐。
3.根据权利要求1所述的应用，其特征在于，所述应用选自：脂糖素在降低血清中血清中谷丙转氨酶及谷草转氨酶水平、改善脂肪变性程度、改善肝小叶炎症程度、降低肝细胞气球样变性程度和改善肝脏损伤程度中的应用。
4.根据权利要求1所述的应用，其特征在于，所述的非酒精性脂肪肝炎，选自肝炎引起的非酒精性脂肪肝炎、肥胖症引起的非酒精性脂肪肝炎、糖尿病引起的非酒精性脂肪肝炎、胰岛素抵抗引起非酒精性脂肪肝炎、高甘油三酯血症引起的非酒精性脂肪肝炎、无β脂蛋白血症引起的非酒精性脂肪肝炎、糖原贮积病引起的非酒精性脂肪肝炎、韦克病引起的非酒精性脂肪肝炎、沃尔曼病引起的非酒精性脂肪肝炎或脂肪营养不良所引起的非酒精性脂肪肝炎。
5.根据权利要求1所述的应用，其特征在于，其中所述药物为含有脂糖素或其药用盐作为药物活性成分的的药物组合物。
6.根据权利要求5所述的应用，其特征在于，所述药物组合物可以被制备成任何一种可药用的剂型。
7.根据权利要求6所述的应用，其特征在于，所述剂型选自：片剂、胶囊剂、颗粒剂、丸剂、散剂、膏剂、丹剂、注射剂、栓剂、喷雾剂、滴剂、贴剂、滴丸剂。
8.根据权利要求7所述的应用，其特征在于，所述剂型选自粉针或液体针。
9.根据权利要求8所述的应用，其特征在于，所述液体针选自水针，有机溶剂针，混悬液针。
Priority Applications (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710172824.0A CN108619490A (zh) | 2017-03-22 | 2017-03-22 | 一种长效化突变的人源成纤维生长因子的新用途 |
| CN201880013016.2A CN110520146A (zh) | 2017-03-22 | 2018-03-19 | 一种长效化突变的人源成纤维生长因子的新用途 |
| EP18771156.9A EP3603660B1 (en) | 2017-03-22 | 2018-03-19 | Long-acting mutant human fibroblast growth factor 21 for treating non-alcoholic steatohepatitis |
| RU2019125343A RU2785582C2 (ru) | 2017-03-22 | 2018-03-19 | Применение пегилированного рекомбинантного химерного фактора роста фибробластов-21 мыши или его фармацевтически приемлемой соли в составе лекарственных средств для лечения неалкогольного стеатогепатита |
| JP2020500949A JP7491839B2 (ja) | 2017-03-22 | 2018-03-19 | 長期作用型の変異ヒト由来線維芽細胞増殖因子の新規な用途 |
| CA3049703A CA3049703A1 (en) | 2017-03-22 | 2018-03-19 | New use of a long-acting mutant human fibroblast growth factor |
| PCT/CN2018/079482 WO2018171557A1 (zh) | 2017-03-22 | 2018-03-19 | 一种长效化突变的人源成纤维生长因子的新用途 |
| US16/520,053 US12152059B2 (en) | 2017-03-22 | 2019-07-23 | Method of treating nash using a long-acting mutant human fibroblast growth factor |
| US18/920,806 US20250042964A1 (en) | 2017-03-22 | 2024-10-18 | Method of treating nash using a long-acting mutant human fibroblast growth factor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710172824.0A CN108619490A (zh) | 2017-03-22 | 2017-03-22 | 一种长效化突变的人源成纤维生长因子的新用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108619490A true CN108619490A (zh) | 2018-10-09 |
Family
ID=63585053
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710172824.0A Pending CN108619490A (zh) | 2017-03-22 | 2017-03-22 | 一种长效化突变的人源成纤维生长因子的新用途 |
| CN201880013016.2A Pending CN110520146A (zh) | 2017-03-22 | 2018-03-19 | 一种长效化突变的人源成纤维生长因子的新用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880013016.2A Pending CN110520146A (zh) | 2017-03-22 | 2018-03-19 | 一种长效化突变的人源成纤维生长因子的新用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12152059B2 (zh) |
| EP (1) | EP3603660B1 (zh) |
| JP (1) | JP7491839B2 (zh) |
| CN (2) | CN108619490A (zh) |
| CA (1) | CA3049703A1 (zh) |
| WO (1) | WO2018171557A1 (zh) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8951966B2 (en) | 2011-07-01 | 2015-02-10 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| WO2014085365A2 (en) | 2012-11-28 | 2014-06-05 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| DK2938740T3 (da) | 2012-12-27 | 2022-06-20 | Ngm Biopharmaceuticals Inc | Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| CA3034399A1 (en) | 2016-08-26 | 2018-03-01 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN108619490A (zh) * | 2017-03-22 | 2018-10-09 | 天士力医药集团股份有限公司 | 一种长效化突变的人源成纤维生长因子的新用途 |
| CN120713840B (zh) * | 2025-03-26 | 2025-11-25 | 天士力医药集团股份有限公司 | 一种PEG-hmFGF-21注射液及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103193878A (zh) * | 2013-04-03 | 2013-07-10 | 哈尔滨博翱生物医药技术开发有限公司 | 突变hFGF-21蛋白成熟肽及其与聚乙二醇的交联物以及它们的应用 |
| CN103415300A (zh) * | 2010-07-20 | 2013-11-27 | 诺沃—诺迪斯克有限公司 | N-末端修饰的fgf21化合物 |
| CN103923207A (zh) * | 2014-04-08 | 2014-07-16 | 东北农业大学 | 一种fgf-21突变体蛋白的制备及其在治疗非酒精性脂肪肝中的应用 |
| WO2015127474A1 (en) * | 2014-02-24 | 2015-08-27 | Energesis Pharmaceuticals, Inc. | Methods and compositions for inducing differentiation of human brown adipocyte progenitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716626B1 (en) * | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| CA2557782A1 (en) * | 2004-03-17 | 2005-10-06 | Eli Lilly And Company | Glycol linked fgf-21 compounds |
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| WO2011154349A2 (en) * | 2010-06-08 | 2011-12-15 | Novo Nordisk A/S | Fgf21 analogues and derivatives |
| EP2440235A1 (en) * | 2009-06-11 | 2012-04-18 | Novo Nordisk A/S | Glp-1 and fgf21 combinations for treatment of diabetes type 2 |
| CN103124562A (zh) * | 2010-06-08 | 2013-05-29 | 诺沃—诺迪斯克有限公司 | Fgf21的类似物和衍生物 |
| CN101935346B (zh) * | 2010-08-24 | 2012-08-08 | 哈尔滨博翱生物医药技术开发有限公司 | 突变的人源成纤维生长因子及在治疗内分泌疾病中的用途 |
| JP6822839B2 (ja) * | 2013-09-13 | 2021-01-27 | ザ・スクリップス・リサーチ・インスティテュート | 修飾された治療剤、及びその組成物 |
| UY36370A (es) * | 2014-10-24 | 2016-04-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Polipéptidos fgf-21 modificados y sus usos |
| CN108619490A (zh) * | 2017-03-22 | 2018-10-09 | 天士力医药集团股份有限公司 | 一种长效化突变的人源成纤维生长因子的新用途 |
-
2017
- 2017-03-22 CN CN201710172824.0A patent/CN108619490A/zh active Pending
-
2018
- 2018-03-19 WO PCT/CN2018/079482 patent/WO2018171557A1/zh not_active Ceased
- 2018-03-19 CA CA3049703A patent/CA3049703A1/en active Pending
- 2018-03-19 JP JP2020500949A patent/JP7491839B2/ja active Active
- 2018-03-19 EP EP18771156.9A patent/EP3603660B1/en active Active
- 2018-03-19 CN CN201880013016.2A patent/CN110520146A/zh active Pending
-
2019
- 2019-07-23 US US16/520,053 patent/US12152059B2/en active Active
-
2024
- 2024-10-18 US US18/920,806 patent/US20250042964A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103415300A (zh) * | 2010-07-20 | 2013-11-27 | 诺沃—诺迪斯克有限公司 | N-末端修饰的fgf21化合物 |
| CN103193878A (zh) * | 2013-04-03 | 2013-07-10 | 哈尔滨博翱生物医药技术开发有限公司 | 突变hFGF-21蛋白成熟肽及其与聚乙二醇的交联物以及它们的应用 |
| WO2015127474A1 (en) * | 2014-02-24 | 2015-08-27 | Energesis Pharmaceuticals, Inc. | Methods and compositions for inducing differentiation of human brown adipocyte progenitors |
| CN103923207A (zh) * | 2014-04-08 | 2014-07-16 | 东北农业大学 | 一种fgf-21突变体蛋白的制备及其在治疗非酒精性脂肪肝中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US12152059B2 (en) | 2024-11-26 |
| US20190367574A1 (en) | 2019-12-05 |
| JP2020511545A (ja) | 2020-04-16 |
| CN110520146A (zh) | 2019-11-29 |
| US20250042964A1 (en) | 2025-02-06 |
| EP3603660A1 (en) | 2020-02-05 |
| RU2019125343A3 (zh) | 2021-03-31 |
| EP3603660B1 (en) | 2025-01-15 |
| CA3049703A1 (en) | 2018-09-27 |
| JP7491839B2 (ja) | 2024-05-28 |
| EP3603660A4 (en) | 2021-01-13 |
| WO2018171557A1 (zh) | 2018-09-27 |
| RU2019125343A (ru) | 2021-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108619490A (zh) | 一种长效化突变的人源成纤维生长因子的新用途 | |
| JP6794366B2 (ja) | シリビン、ｌ−カルニチンを含有する薬物組成物 | |
| US11351184B2 (en) | Preparation of Pulsatilla saponin B4 for injection | |
| KR102676056B1 (ko) | 비알코올성 지방간 질환의 치료 또는 예방용 의약의 제조에서의 트리아세틸-3-하이드록시페닐아데노신의 용도 | |
| CN113768956B (zh) | 无细胞脂肪提取液对巨噬细胞极化调节与疾病治疗的作用 | |
| EP4663188A1 (en) | Use of silybum marianum pharmaceutical composition in preparation of drugs for treating fatty liver diseases | |
| CN109200273B (zh) | 一种多肽用于制备预防或治疗脂肪肝病药物的用途 | |
| CN115607546A (zh) | Isarubrolone C、包含Isarubrolone C的药物组合物及应用 | |
| CN116459249A (zh) | 黄连素及其衍生物在制备促骨骼肌生长产品的用途 | |
| BRPI0713647A2 (pt) | formulações farmacêuticas e composições de um antagonista seletivo cxcr2 ou cxcr1 e métodos para o uso do mesmo visando o tratamento de distúrbios inflamatórios | |
| RU2785582C2 (ru) | Применение пегилированного рекомбинантного химерного фактора роста фибробластов-21 мыши или его фармацевтически приемлемой соли в составе лекарственных средств для лечения неалкогольного стеатогепатита | |
| CN104739813A (zh) | 四氢姜黄素的新用途 | |
| CN119405816B (zh) | 一种降尿酸的药物组合物及其制备方法、应用和产品 | |
| CN113332416B (zh) | 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用 | |
| CN115737698B (zh) | 一种铁甲草提取物在抑制葡萄糖苷酶中的应用 | |
| CN1317960A (zh) | 用于改善胰岛素敏感性和葡萄糖代谢的含有d－手性肌醇的药物组合物 | |
| KR102693566B1 (ko) | 지방간 질환의 예방 또는 치료를 위한 약학적 조성물 | |
| CN120093765A (zh) | 瑞司美替罗联合二甲双胍或其药学上可接受的盐在制备药物中的应用 | |
| CN119679716A (zh) | 一种缓释型氯舒隆纳米制剂及其制备方法 | |
| CN120919192A (zh) | 芹槐提取物在制备治疗代谢功能障碍相关的脂肪性肝病的药物中的用途 | |
| CN120531747A (zh) | 一种基于白头翁皂苷与联苯双酯的协同药物组合物及其在治疗急性肝损伤中的应用 | |
| CN120168530A (zh) | 姬松茸提取物及其治疗肠黏膜炎的用途 | |
| CN118416090A (zh) | 贝莱斯芽孢杆菌胞外多糖在预防或治疗代谢紊乱中的用途 | |
| CN111053781A (zh) | 连翘酯苷a的新用途 | |
| CN115645449A (zh) | 一种双辅料酒蜜制山萸肉炮制方法及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190514 Address after: 201203 No. 1 and No. 2 Juli Road, China (Shanghai) Free Trade Pilot Area, Pudong New Area, Shanghai Applicant after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin Beichen District Huaihe road and Ting Jiang West Road intersection heaven proud of the park Legal Center Intellectual Property Department Applicant before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181009 |
|
| WD01 | Invention patent application deemed withdrawn after publication |